Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Poland's Diagnostyka plans IPO on Warsaw bourse
    Finance

    Poland's Diagnostyka plans IPO on Warsaw bourse

    Published by Global Banking & Finance Review®

    Posted on January 24, 2025

    2 min read

    Last updated: January 27, 2026

    The featured image illustrates Poland's Diagnostyka, a leader in medical diagnostics, announcing its IPO on the Warsaw Stock Exchange to enhance market position and shareholder value.
    Poland's Diagnostyka medical diagnostics firm plans IPO on Warsaw bourse - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Diagnostyka plans an IPO on the Warsaw Stock Exchange, selling existing shares to support growth and increase shareholder value.

    Diagnostyka Announces IPO Plans on Warsaw Bourse

    GDANSK (Reuters) - Polish medical diagnostics firm Diagnostyka is planning an initial public offer (IPO) on the Warsaw Stock Exchange, the company said on Monday.

    "The planned IPO is an important step to support the further development of the company and help us continue to strengthen our position in the market and increase shareholder value," CEO Jakub Swadzba said in a statement.

    The planned offering will involve the sale of existing shares held by LX Beta S.à r.l., controlled by the MidEuropa III Management Limited, which currently holds 47.83% of Diagnostyka's shares.

    Diagnostyka said it would not issue or offer new shares in connection with the IPO.

    The offering will be addressed to retail and institutional investors in Poland and select international markets, with some 5% to 10% of the shares allocated to retail investors, it said.

    The Diagnostyka Group, which started operations in 1998, said it was a market leader in Poland's medical diagnostics industry with more than 1,100 blood collection points, 156 laboratories and 19 imaging facilities.

    It reported revenue of 1.6 billion zlotys ($382.9 million) in 2023 and 1.46 billion zlotys in the first nine months of 2024.

    ($1 = 4.1787 zlotys)

    (Reporting by Marta Maciag; editing by Milla Nissi)

    Key Takeaways

    • •Diagnostyka plans IPO on Warsaw Stock Exchange.
    • •Existing shares held by LX Beta S.à r.l. to be sold.
    • •No new shares will be issued in the IPO.
    • •Offering targets retail and institutional investors.
    • •Diagnostyka is a market leader in Poland's diagnostics industry.

    Frequently Asked Questions about Poland's Diagnostyka plans IPO on Warsaw bourse

    1What is the main topic?

    The article discusses Diagnostyka's plans to launch an IPO on the Warsaw Stock Exchange to support its growth and market position.

    2Who is selling shares in the IPO?

    Existing shares held by LX Beta S.à r.l., controlled by MidEuropa III Management Limited, will be sold.

    3Will Diagnostyka issue new shares?

    No, Diagnostyka will not issue or offer new shares in connection with the IPO.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    View All Finance Posts
    Previous Finance PostPorsche's 2024 China sales fall by 28%
    Next Finance PostNorwegian Air cuts 2024 operating profit forecast